Aishwarya Ghosh, Simon Erridge, Ross Coomber, Urmila Bhoskar, Wendy Holden, Fariha Kamal, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, Azfer Usmani, James Rucker, Mikael Sodergren
{"title":"UK Medical Cannabis Registry: A Clinical Analysis of Patients with Substance Use Disorder.","authors":"Aishwarya Ghosh, Simon Erridge, Ross Coomber, Urmila Bhoskar, Wendy Holden, Fariha Kamal, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, Azfer Usmani, James Rucker, Mikael Sodergren","doi":"10.1159/000547696","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>With a global rise in opioid-related mortality, there comes a need to address this with novel therapies. Cannabinoid receptors are highly expressed and co-localised with opiate receptors of the mesolimbic system. Cannabis-based medicinal products (CBMPs) have been suggested as a measure to reduce harm as maintenance therapy for substance use disorder (SUD). This aim of this study was to assess changes in patient-reported outcomes measures (PROMs) and opioid medications in individuals treated with CBMPs for SUD.</p><p><strong>Methods: </strong>Data from patients with SUD from the UK Medical Cannabis Registry were analysed. Outcomes included changes at 1, 3, and 6 months from baseline of the EQ-5D-DL, single-item sleep quality scale (SQS), and Generalised Anxiety Disorder-7 (GAD-7) questionnaire. Change in opioid medications was assessed as change in oral morphine equivalent (OME).</p><p><strong>Results: </strong>34 patients were included. Twenty-seven (79.41%) participants were male. Twenty-nine (85.29%) participants were illicit cannabis consumers at baseline. The most common SUD was opioid use disorder (n = 18; 52.94%). Four (11.76%), 14 (41.18%), and 16 (47.05%) patients were prescribed oils, dried flower, or a combination of dried flower and oils, respectively. Improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, and 6 months from baseline were observed (p < 0.050). Median OME consumption at baseline was 274.95 (79.50-441.80) mg/day. This was reduced at 6 months (204.45 [61.88-354.85] mg/day; p = 0.043), there was no significant difference at 1 or 3 months (p > 0.050). Three (8.81%) participants reported 17 (50.00%) adverse events.</p><p><strong>Conclusions: </strong>There was an associated improvement in health-related quality of life PROMs and reduction in prescribed opioids in individuals with SUD treated with CBMPs. CBMPs were well tolerated by most individuals in this 6-month analysis. Further evaluation through randomised controlled trials is needed to determine causality.</p>","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"1-11"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Addiction Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547696","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: With a global rise in opioid-related mortality, there comes a need to address this with novel therapies. Cannabinoid receptors are highly expressed and co-localised with opiate receptors of the mesolimbic system. Cannabis-based medicinal products (CBMPs) have been suggested as a measure to reduce harm as maintenance therapy for substance use disorder (SUD). This aim of this study was to assess changes in patient-reported outcomes measures (PROMs) and opioid medications in individuals treated with CBMPs for SUD.
Methods: Data from patients with SUD from the UK Medical Cannabis Registry were analysed. Outcomes included changes at 1, 3, and 6 months from baseline of the EQ-5D-DL, single-item sleep quality scale (SQS), and Generalised Anxiety Disorder-7 (GAD-7) questionnaire. Change in opioid medications was assessed as change in oral morphine equivalent (OME).
Results: 34 patients were included. Twenty-seven (79.41%) participants were male. Twenty-nine (85.29%) participants were illicit cannabis consumers at baseline. The most common SUD was opioid use disorder (n = 18; 52.94%). Four (11.76%), 14 (41.18%), and 16 (47.05%) patients were prescribed oils, dried flower, or a combination of dried flower and oils, respectively. Improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, and 6 months from baseline were observed (p < 0.050). Median OME consumption at baseline was 274.95 (79.50-441.80) mg/day. This was reduced at 6 months (204.45 [61.88-354.85] mg/day; p = 0.043), there was no significant difference at 1 or 3 months (p > 0.050). Three (8.81%) participants reported 17 (50.00%) adverse events.
Conclusions: There was an associated improvement in health-related quality of life PROMs and reduction in prescribed opioids in individuals with SUD treated with CBMPs. CBMPs were well tolerated by most individuals in this 6-month analysis. Further evaluation through randomised controlled trials is needed to determine causality.
期刊介绍：
''European Addiction Research'' is a unique international scientific journal for the rapid publication of innovative research covering all aspects of addiction and related disorders. Representing an interdisciplinary forum for the exchange of recent data and expert opinion, it reflects the importance of a comprehensive approach to resolve the problems of substance abuse and addiction in Europe. Coverage ranges from clinical and research advances in the fields of psychiatry, biology, pharmacology and epidemiology to social, and legal implications of policy decisions. The goal is to facilitate open discussion among those interested in the scientific and clinical aspects of prevention, diagnosis and therapy as well as dealing with legal issues. An excellent range of original papers makes ‘European Addiction Research’ the forum of choice for all.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
